Will a new lung drug clash with common medicines?
NCT ID NCT07744386
First seen Aug 04, 2026 · Last updated Aug 05, 2026 · Updated 1 time
Summary
This trial is testing whether an experimental drug called CHF10196 changes how the body processes two other medications: dabigatran (a blood thinner) and rosuvastatin (a cholesterol drug). Healthy male volunteers will take these drugs alone and then together with CHF10196, and researchers will measure drug levels in the blood to see if there is any interaction. The goal is to ensure that CHF10196 can be safely used alongside common treatments.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- CHF10196, dabigatran etexilate, and rosuvastatin
- What this could lead to
- If CHF10196 does not interfere with these drugs, it could be safely combined with common medications in future treatments.
- What could go wrong
- This is an early-phase study in a small group of healthy men, so results may not apply to patients or predict real-world outcomes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 1
The first testing in people. Mainly checks safety and dose, usually in a small group.
- Participants
-
About 24 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Oct 2026
An estimate. Start dates often move.
- Expected to finish
-
Dec 2028
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 55 years
- Sex
-
Male participants only
- Healthy volunteers
-
Accepted
You do not need to have the condition being studied to take part.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Healthy male participants aged 18 to 55 years * Body mass index between 18.0 and 30.0 kg/m² * Non-smokers or ex-smokers (\<5 pack-years) * Clinically healthy based on medical history and examination * Vital signs and ECG within normal limits * Willing and able to comply with study procedures Exclusion Criteria: * Use of prohibited concomitant medications * Participation in another clinical study within 3 months * Clinically relevant medical conditions * Abnormal laboratory values * Positive HIV, hepatitis B, or hepatitis C * History of bleeding disorders * Drug or alcohol abuse * Use of nicotine-containing products within defined period * Recent COVID-19 infection
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Healthy male volunteers are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
Fortrea Clinical Research Unit (CRU) Limited
Leeds, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.